Depression's biological fingerprint: a quest for objective diagnosis and personalized treatment

NCT ID NCT07735143

Not yet recruiting Knowledge-focused Sponsor: Shanghai Mental Health Center Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study aims to develop models that combine clinical assessments with biological data (multi-omics) to improve diagnosis of major depressive disorder and predict how patients will respond to antidepressants. Researchers will follow 150 participants aged 14-45 with depression, along with healthy controls, collecting blood samples and clinical evaluations over time. The goal is to identify reliable biomarkers that could one day guide personalized treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to biological tests that help diagnose depression and predict which antidepressant will work for a person.
What could go wrong: This is an observational study, not a treatment trial. The models may not prove accurate enough for routine use, and results may not apply to all age groups or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER (MDD)

Contacts and locations

Locations

Shanghai Mental Health Center

Shanghai, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.